PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Denosumab - Osteoporosis

PAD Profile : Denosumab - Osteoporosis

Keywords :
PSDs, patient specific directions, postmenopausal osteoporosis
Brand Names Include :
Prolia

Traffic Light Status

Status 1 of 1.

Status :
Green (see narrative)
Important
Formulations :
  • Subcutaneous injection (sc)
Important Information :
Patients with a CKD of 4 or 5 and patients with a T-score of < -4.5 to remain under specialist care.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
05 July 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed Denosumab Prescribing Information to support initiation and ongoing administration in primary care.

01 November 2017
Surrey Medicines Commissioners Group

Patient Specific Directions (PSDs) are often used to enable non-medical practitioners (practice nurses, health care assistants) to administer specific medicines for specific conditions. A PSD tempate for EMIS system users has been developed by a local GP practice to improve the consistency and content of their Denosumab PSDs. This PSD template (among others) is available from your local Medicines Management Team should your practice wish to adopt / adapt it. Please contact your local Medicines Management Team for assistance

01 November 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The Osteoporosis guidelines have been reviewed and updated. Denosumab has been included as a treatment option for postmenopausal women and men who are intolerant to two bisphosphonates / or have a contraindication to bisphosphonates. Certain patients should remain under the care of the secondary care clinicians and they include: Renal patients with a CKD of 4 or 5 and patients with a T score of <-4.5. The osteoporosis guidelines are supported by two algorithms (algorithm 1 - Treatment Pathway for adults; algorithm 2 - Review of Long-term Bisphosphonate Therapy) which have been extracted from the guideline and provided as separate documents (below) for ease of use.

Associated BNF Codes

06. Endocrine System
06.06.02. Bisphosphonates and other drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More